drugset
drugset / Trial / NCT01253434

E2022 Patch Formulation Single Dose Phase I Study

NCT01253434 ↗

Phase 1 Completed 80 enrolled Eisai Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of a single dose of E2022 in healthy Japanese male volunteers.

Timeline

Start
2010-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg —

Indications

No indication recorded.